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Abstract
Aims/hypothesis Previous studies have shown that diabetes mellitus destabilises the integrity of the microvasculature in different
organs by damaging the interaction between pericytes and endothelial cells. In bone marrow, pericytes exert trophic functions on
endothelial cells and haematopoietic cells through paracrine mechanisms. However, whether bone marrow pericytes are a target
of diabetes-induced damage remains unknown. Here, we investigated whether type 2 diabetes can affect the abundance and
function of bone marrow pericytes.
Methods We conducted an observational clinical study comparing the abundance and molecular/functional characteristics of
CD146+ pericytes isolated from the bone marrow of 25 individuals without diabetes and 14 individuals with uncomplicated type
2 diabetes, referring to our Musculoskeletal Research Unit for hip reconstructive surgery.
Results Immunohistochemistry revealed that diabetes causes capillary rarefaction and compression of arteriole size in
bone marrow, without changing CD146+ pericyte counts. These data were confirmed by flow cytometry on freshly
isolated bone marrow cells. We then performed an extensive functional and molecular characterisation of
immunosorted CD146+ pericytes. Type 2 diabetes caused a reduction in pericyte proliferation, viability, migration
and capacity to support in vitro angiogenesis, while inducing apoptosis. AKT is a key regulator of the above
functions and its phosphorylation state is reportedly reduced in the bone marrow endothelium of individuals with
diabetes. Surprisingly, we could not find a difference in AKT phosphorylation (at either Ser473 or Thr308) in bone
marrow pericytes from individuals with and without diabetes. Nonetheless, the angiocrine signalling reportedly
associated with AKT was found to be significantly downregulated, with lower levels of fibroblast growth factor-2
(FGF2) and C-X-C motif chemokine ligand 12 (CXCL12), and activation of the angiogenesis inhibitor angiopoietin
2 (ANGPT2). Transfection with the adenoviral vector carrying the coding sequence for constitutively active
myristoylated AKT rescued functional defects and angiocrine signalling in bone marrow pericytes from diabetic
individuals. Furthermore, an ANGPT2 blocking antibody restored the capacity of pericytes to promote endothelial
networking.
Conclusions/interpretation This is the first demonstration of pericyte dysfunction in bonemarrow of people with type 2 diabetes.
An altered angiocrine signalling from pericytes may participate in bone marrow microvascular remodelling in individuals with
diabetes.
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Abbreviations
Ad-myrAKT Adenoviral vector carrying the coding
sequence for constitutively active
myristoylated Akt
Ad-Null Adenoviral empty vector
ANGPT1 Angiopoietin 1
ANGPT2 Angiopoietin 2
BM-MNC Bone marrow mononuclear cell
CXCL12 Chemokine (C-X-C motif) ligand 12
DLK1 Delta-like 1
DLK4 Delta-like 4
FGF2 Fibroblast growth factor 2
HSPC Haematopoietic stem/progenitor cell
IGFBP2 Insulin-like growth factor-binding
protein 2
JAG1 Jagged 1
KITLG Stem cell factor–KIT ligand
LEPROT Leptin receptor
NG2 Neural/glial antigen 2
PDGFB Platelet-derived growth factor B
PDGFRα Platelet-derived growth factor receptor α
PDGFRβ Platelet-derived growth factor receptor β
PGP9.5 Protein gene product 9.5
qPCR Quantitative PCR
SEMA Semaphorin
αSMA α-Smooth muscle actin protein
TIE2 Tyrosine kinase with immunoglobulin
and epidermal growth factor homology
domain-2
VE-cadherin Vasclular endothelial-cadherin
VEGF Vascular endothelial growth factor
VEGFR2 Vascular endothelial growth factor
receptor 2
VWF von Willebrand factor
Introduction
Diabetes mellitus represents an international health burden [1,
2], with cardiovascular disease remaining the most prevalent
cause of morbidity and mortality [3].
Pathological phenomena affecting the bone marrow con-
tribute to cardiovascular complications in people with diabetes
[4–7]. Fadini and colleagues demonstrated that levels of cir-
culating bone marrow-derived proangiogenic cells inversely
correlate with complications in the coronary, peripheral and
cerebrovascular regions [8]. Moreover, reduced counts of cir-
culating CD34+ haematopoietic stem/progenitor cells
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(HSPCs) predict mortality in diabetic individuals [9], an asso-
ciation confirmed by a meta-analysis of 21 studies [10].
Reciprocally, the bone marrow represents a previously un-
foreseen target of diabetes-induced microvascular damage. A
specific form of microangiopathy occurs in the bone marrow
of diabetic mice [11]. In individuals with type 2 diabetes, bone
marrow microangiopathy is associated with fat accumulation
and apoptotic reduction of CD34+ haematopoietic cells
[12–14]. Oxidative stress plays a pivotal role in the pathogen-
esis of bone marrow microangiopathy through the reduction
of AKT phosphorylation/activity in endothelial cells [15, 16].
There are reports indicating pericyte loss and microaneurysm
formation in the retina, kidney and brain of diabetic individ-
uals [17, 18]. However, no previous investigation has deter-
mined the impact of type 2 diabetes on pericytes in human
bone marrow.
Distinct pericyte-like cells have been described in the vas-
cular niche of the murine bone marrow [19–24]. Vascular
sinusoids are surrounded by leptin receptor (LEPROT)–plate-
let-derived growth factor receptor α (PDGFRα)-expressing
cells [22, 25] and chemokine (C-X-C motif) ligand 12
(CXCL12)-abundant reticular cells [24]. An additional sub-
type reportedly resides in the proximity of bone marrow arte-
rioles, is surrounded by neuronal fibres and expresses neural/
glial antigen 2 (NG2) and nestin [26]. Two independent
groups reported that human bone marrow contains clonogenic
pericytes, which express the adhesion molecule CD146 to-
gether with the mesenchymal/pericyte markers α-smooth
muscle actin (αSMA), NG2 and platelet-derived growth fac-
tor receptor β (PDGFRβ) but are negative for the
haematopoietic and endothelial markers CD45, CD34 and
CD31 [27, 28]. Bone marrow pericytes play key roles in the
control of vascular tone and permeability and participate in the
regulation of haematopoiesis through a molecular signalling
involving CXCL12, stem cell factor–KIT ligand (KITLG) and
angiopoietin 1 (ANGPT1) [29–32]. In vitro, bone marrow
pericytes show tri-lineage mesenchymal differentiation poten-
tial and, upon transplantation into immunodeficient mice, they
reportedly promote the formation of heterotopic
haematopoietic niches through paracrine mechanisms [23,
28, 33].
This translational study aimed to compare the abundance
and molecular/functional diversity of bone marrow pericytes
from individuals with or without type 2 diabetes.
Methods
Ethics
Patients undergoing hip replacement surgery were recruited to
the study, under informed written consent, at the Avon
Orthopaedic Centre, Southmead Hospital, Bristol, UK. The
study protocol complied with principles of the Declaration
of Helsinki, was covered by institutional ethical approval
(REC14/SW/1083 and REC14/WA/1005) and was registered
as an observational clinical study in the NIHR Clinical
Research Network Portfolio, UK Clinical Trials Gateway.
Inclusion and exclusion criteria
The main clinical characteristics of the participants are
included in Table 1. Type 2 diabetes was diagnosed
according to the American Diabetes Association guide-
lines and was defined as follows: (1) patient/referring
doctor reports a previous diagnosis of diabetes; (2)
HbA1c >48 mmol/mol (9.3%) and (3) off insulin for at
least 12 months after diagnosis. Exclusion criteria com-
prised acute disease/infection, immune diseases, haema-
tological disorders or malignancy, unstable angina, re-
cent (within 6 months) myocardial infarction or stroke,
critical limb ischaemia, liver failure, renal failure, preg-
nancy and lack of consent to participate. Randomisation
was not required in the experimental plan. At all the
occasions, a single patient’s sample was delivered from
the Orthopaedic Centre to our laboratory and freshly
processed according to the described protocols.
Experimenters were aware the sample was from a dia-
betic or non-diabetic individual. Measurements were
taken from distinct samples and each sample was gen-
erally measured in duplicate or triplicate, unless speci-
fied differently.
Tissue processing
The femoral head was removed as a standard step of hip re-
placement surgery. Bone marrow was scooped into a sterile
pot, transferred into Falcon tubes containing PBS-EDTA
(ThermoFisher, Gloucester, UK, catalogue number 28348)
and placed in a fridge for collection within 1 h. Only material
otherwise discarded was collected for the study.
Table 1 Characteristics of participants
Characteristic Without diabetes With diabetes
Participants, n 25 14
Age, years 65 ± 2 (39–84) 67 ± 3 (41–79)
Men/women, n 11/14 7/7
BMI, kg/m2 29 ± 1 (21–42) 33 ± 2 (24–44)
HbA1c, mmol/mol 40 ± 1 60 ± 4
HbA1c, % 8.6 10.4
Data are mean±SD (range) or mean±SD, unless stated otherwise
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Cell isolation and expansion
Bone marrow samples were stratified on Ficoll Histopaque 1077
(Sigma-Aldrich, St. Louis, MO, USA, catalogue number 10771)
and centrifuged at 300 g for 30 min at 25°C. Mononuclear cells
sedimented at the interphase were then collected, washed twice
with PBS and assessed for viability by trypan blue staining
(ThermoFisher, catalogue number 15250061). An average of
1 × 108 bone marrow mononuclear cells (BM-MNCs) was la-
belled with CD34-conjugated microbeads (Miltenyi, Woking,
UK) and immunomagnetically sorted. CD34-depleted cells were
labelled with CD45-conjugated microbeads (Miltenyi) and fur-
ther sorted. The CD34–CD45 double-negative population was
labelled with CD146-conjugated microbeads (Miltenyi) and
enriched through immunomagnetic sorting. The purity of the
selected cell population was assessed by flow cytometry (see
below). Samples with a purity below 90% were excluded from
the study.
The CD34−CD45−CD146+ cell fraction was then seeded
onto 24-well plates at a density of 1 × 103 to 5 × 103 cells
per cm2 and expanded in an α-MEM basal media
(ThermoFisher Scientific, catalogue number 32561-029) sup-
plemented with 20% FBS (ThermoFisher Scientific, catalogue
number 16000044). Four to six cell lines per group were stud-
ied between passage three and seven in the subsequent
experiments.
Flow cytometry
Bone marrow mononuclear cells were labelled with primary
antibodies (ESM Table 1) in staining buffer (PBS supplement-
ed with 1% bovine serum albumin, Sigma, catalogue number
A2058) for 30 min at 4°C, washed with cold PBS and resus-
pended in staining buffer. They were then acquired using a
FACScantoII (BD Biosciences, Wokingham, UK).
Quantification was performed using the FlowJo v10 software
(FlowJo, Ashland, OR, USA). Flow cytometry antibodies
used are reported in ESM Table 1.
Western blot analyses
Protein extracts (20 μg) were separated by SDS-PAGE, trans-
ferred to PVDF membranes (Amersham-Pharmacia) and then
probed with the antibodies listed in ESM Table 2.
Immunohistochemistry
Portions of bone marrow were fixed in formalin 37% for 16 h,
decalcified in 20% EDTA – 2% HCl solution for 4 h and then
embedded in paraffin. The samples were sectioned on a rotary
microtome at 2 μm, dried, deparaffinised and rehydrated.
Antigen retrieval was performed by boiling the samples in a
citrate buffer (10 mmol/l, Sigma, catalogue number P4809) at
pH 6. After blocking non-specific binding with non-immune
goat serum (ThemoFisher, catalogue number 10000C), sec-
tions were washed and then incubated with the following pri-
mary antibodies indicated in ESM Table 3: polyclonal mouse
anti-human melanoma cell adhesion molecule (MCAM, BD
Biosciences), polyclonal rabbit anti-von Willebrand factor
(VWF, Abcam, Cambridge, UK), rabbit monoclonal anti-
CD146 (Abcam), mouse monoclonal anti-protein gene prod-
uct 9.5 (PGP9.5, Abcam), or monoclonal mouse anti-αSMA
(Dako, Ely, UK) in PBS. All incubations were performed
overnight at 4°C. The proper secondary antibodies (ESM
Table 3), goat anti-rabbit or anti-mouse IgG (Alexa Fluor la-
belled), diluted 1:200 in PBS, were incubated for 60 min at
37°C. Nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI, 1 μg/μl, ThermoFisher, Catalogue num-
ber D1306). To remove the excess of autofluorescence, the
bone marrow sections were immersed in a solution of 0.1%
wt/vol. Sudan black (Sigma-Aldrich, catalogue number
86015) in 70% ethanol for 10 min at room temperature.
Immunocytochemistry
Cells were seeded in eight-chamber slides, grown until con-
fluence and then fixed with 4% wt/vol. paraformaldehyde for
15 min at room temperature. This step was followed by an
incubation overnight at 4°C with the primary antibodies re-
ported in ESM Table 3: rabbit anti-human CD146 (Abcam),
rabbit anti-human CXCL12 (Cell Technologies, Cambridge,
UK), rabbit anti-human vasclular endothelial-cadherin (VE-
cadherin, Abcam), mouse anti-human nestin (Abcam), rabbit
anti-human PDGFRβ (Santa Cruz, Heidelberg, Germany),
rabbit-anti-human vascular endothelial growth factor receptor
2 (VEGFR2, Abcam), rabbit LEPROT (Abcam), and mouse
VWF (Abcam). All incubations were performed overnight at
4°C in PBS. Then, the cells were washed with PBS and incu-
bated with appropriate secondary antibody diluted 1:200 in
PBS for 2 h at room temperature. Finally, cells were washed
with PBS and counterstained with DAPI 1 μg/μl, for 1 min at
room temperature. Images of random fields were obtained at
×200 magnification. Antibodies were validated previously by
using negative and/or positive cell cultures as controls, ac-
cording to the literature. Negative controls have been per-
formed for each immunohistochemistry and immunocyto-
chemistry experiment omitting the primary antibody.
Viral infection
Bone marrow CD146+ cells were infected with an adenoviral
vector carrying the coding sequence for constitutively active
myristoylated AKT (Ad-myrAKT) or the empty vector Ad66
(Ad-Null) as a control (both from Addgene, Watertown, MA,
USA). Cells were grown in completemedium in six-well plates
until reaching 60–70% confluence and then infected for 24 h
Diabetologia
with adenoviral vectors at 100 multiplicity of infection. The
mediumwas then changed and cells were used for experiments
after 48 h. Effective expression of the transgene was confirmed
by an activity assay, as previously reported [15].
Functional assays
All the assays were performed with cells maintained in
5 mmol/l glucose.
Viability A colorimetric method (MTS assay; Promega,
Southampton, UK) was used for determining the number of
viable cells. A total of 3 × 104 cells was seeded into 96-well
plates in quadruplicate. The absorbance was measured at λ
492 nm using a microplate reader (Multiskan Ascent;
ThermoFisher Scientific).
Proliferation The bromodeoxyuridine/5-bromo-2 ′-
deoxyuridine (BrdU, Sigma-Aldrich) colourimetric assay
was used to measure proliferation. The absorbance of the
samples was measured in a microplate reader at 370 nm.
Apoptosis Confluent cells were trypsinised and counted with
trypan blue. Cells were washed twice with cold PBS and re-
suspended in 1X Annexin V Buffer (ThermoFisher Scientific)
at 1 × 106 cells/ml. Following this, 5 μl of FITC-conjugated
Annexin V (BD Biosciences) was added to 100 μl of the cell
suspension. Samples were acquired on a FACSCanto II flow
cytometer and 1:400 wt/vol. propidium iodide staining solu-
tion (Invitrogen, Waltham, MA, USA) was added before the
acquisition. Annexin V-positive/propidium iodide-negative
cells were considered to be apoptotic. Results were analysed
using FlowJo v10.
Migration Cells were seeded on the upper part of 24-transwell
plate filters pre-coated with fibronectin. The lower wells
contained basal medium supplemented with recombinant
PDGFB (100 ng/ml; Peprotech, London, UK) as
chemoattractant. After overnight incubation, five random fields
of the filter were counted at magnification ×200 per each filter
using an Olympus BX40 microscope (Southend-on-Sea, UK).
In vitro network formation on Matrigel HUVECs were pur-
chased from Lonza (catalogue number C2519A) and checked
for exclusion of mycoplasma infection. Expanded
CD34−CD45−CD146+ cells (1 × 104) and human umbilical
vein endothelial cells (HUVECs, 2 × 104) or HUVECs alone
(3 × 104) were suspended in a total volume of 100 μl α-
minimal essential medium (αMEM) or in 50 μl of αMEM
plus 50 μl of conditioned medium obtained from expanded
CD146+ cells. The suspension was then added on top of
100 μl gelified, growth-enriched Matrigel (BD Biosciences)
in each well of 96-well plate. Images were obtained using an
inverted microscope (Zeiss, Birmingham, UK) at magnifica-
tion ×200. In selected experiments, the assay was conducted
in the presence of a blocking angiopoietin 2 (ANGPT2) anti-
body (1 μg/ml; ThermoFisher, catalogue number, PA1-
20178) or goat IgG isotype control (1 μg/ml; Thermo Fisher,
catalogue 02-6202).
Gene expression analysis
RNA extraction and purification RNA was extracted from
immunosorted bone marrow pericytes following the QIAzol
protocol and resuspended in 200 μl RNase-free H2O (DEPC-
treated; ThermoFisher). Further purification was achieved
using an acid-phenol/chloroform phase separation method.
A NanoDrop 1000 spectrophotometer (Thermo Scientific)
was used to quantify RNA and assess purity by 260/280 nm
and 260/230 nm ratios.
cDNA reverse transcription The High-Capacity RNA-to-
cDNA Kit (Applied Biosystems, Warrington, UK) was used
for complementary DNA (cDNA) synthesis.
Quantitative PCR Quantitative PCR (qPCR) was used to
measure the gene expression in CD146 immunosorted
pericytes. Primers are shown in ESM Table 4 (all from
Sigma-Aldrich, Gillingham, UK). The experiment was
done using three to six biological samples per experi-
mental group. The qPCR analysis was performed using
relative quantification. The fold-differences between
cells from participants with and without diabetes were
evaluated by the Livak method (2−ΔΔCt ). GAPDH and
18s rRNA were used as housekeeping genes.
ELISA on conditioned media
Fibroblast growth factor 2 (FGF2), vascular endothelial
growth factor (VEGF) A and B, CXCL12, ANGPT1,
ANGPT2, IGFBP2 and SEMA6 were quantified using indi-
vidual cytokine-specific ELISA kits (R&D Systems,
Abingdon, UK).
Statistical analysis
A Kolmogorov–Smirnov test was used to assess whether the
data had a parametric distribution. Values are presented as
mean ± SEM. Two-tailed independent samples t test was used
to compare two groups assuming equal variances. ANOVA
was used to compare multiple groups experiments, followed
by Bonferroni post hoc t test to compare each group individ-
ually. All analyses were carried out using GraphPad Prism 7.0
(San Diego, CA, USA). A p value of <0.05 was considered
statistically significant.
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Results
Immunohistochemistry of pericytes in human bone
marrow
By immunofluorescence microscopy, we verified that
pericytes expressing CD146, CXCL12, nestin and αSMA lo-
calise around capillaries and in the proximity of PGP9.5-pos-
itive neuronal fibres in the bone marrow of diabetic and non-
diabetic individuals (Fig. 1a–c).
Diabetes has profound remodelling effects on the
bone marrow microvasculature [11, 34]. However, the
impact on pericytes has not been previously investigat-
ed. We stained bone marrow samples using CD146 and
VWF antibodies to distinguish endothelial cells (positive
for both the antigens) from pericytes (expressing CD146
only) (Fig. 2c). As previously described [11, 12, 34],
we observed a decrease in VWF-positive capillaries in
the bone marrow of the diabetic compared with non-
diabetic individuals (0.9 ± 0.15 vs1.27 ± 0.16 capillaries/
μm2, p < 0.05) (Fig. 2d). The size of arterioles was re-
duced in the diabetic group (Fig. 2e). However, we did
not observe any difference in the localisation or density
of CD146+ VWF− pericytes between the two groups.
Flow cytometry quantification of pericytes
within freshly collected total bone marrow
mononuclear cells
We next performed flow cytometry analysis of the abundance
of pericytes within bone marrow mononuclear cells. Fig. 3a–e
shows the gating strategy and Fig. 3f–i illustrates the individ-
ual values from different bone marrow samples for the rate of
CD146+ (Fig. 3f), CD34−CD146+ (Fig. 3g), CD45−CD146+
(Fig. 3h) and CD34−CD45−CD146+ cells (Fig. 3i), the latter
combination being previously used to identify human bone
marrow pericytes [33]. There was no difference in the number
of CD34−CD45−CD146+ pericytes from non-diabetic vs dia-
betic individuals: CD34−CD45−CD146+ pericytes accounted
for 0.50 ± 0.19% (non-diabetic) and 0.33 ± 0.15% (diabetic)
of total BM-MNCs (Fig. 3i).
Flow cytometry antigenic characterisation
of expanded bone marrow CD146+ pericytes
We next assessed the antigenic profile of CD146+
immunosorted bone marrow pericytes after expansion in cul-
ture. Flow cytometry analyses confirmed the maintenance of
CD146 abundance in cells from non-diabetic (92.8 ± 1.8%) and
diabetic individuals (94.5 ± 1.9%) (Fig. 4a,b). The expanded
cells were also strongly positive for mesenchymal markers,
such as CD105 (non-diabetic, 74.0 ± 8.1%; diabetic, 76.3 ±
2.2%), CD73 (non-diabetic, 79.9 ± 5.3%; diabetic, 78.8 ±
2.8%) and CD44 (non-diabetic, 74.6 ± 5.0%; diabetic, 70.0 ±
5.5%). Both groups lacked expression of haematopoietic and
endothelial markers. Fluorescent immunocytochemistry
showed that bone marrow pericytes expressed NG2 as well as
nestin, LEPROT, PDGFRβ and VEGFR2 but were negative
for VWF and VE-cadherin (Fig. 4c). The CXCL12 signal was
almost absent in CD146+ pericytes from diabetic individuals.
The reduction in CXCL12 expression was confirmed by qPCR
and ELISA (see below).
Diabetes causes dysfunction of bone marrow
pericytes
We next investigated the impact of diabetes on pericytes’
function. Both viability and proliferation were significantly
reduced in pericytes from diabetic individuals (p < 0.05 for
Fig. 1 Characterisation of bone marrow pericytes in situ. Representative
fluorescence microscopy images showing expression of CD146 (a),
CXCL12 (b) and nestin (c) by cells localised around bone marrow cap-
illaries of non-diabetic and diabetic individuals. Scale bars, 20 μm. ND,
non-diabetic; T2D, type 2 diabetes
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both comparisons, Fig. 5a,b), which also showed a fourfold
increase in the abundance of late apoptotic (Annexin V+/
propidium iodide+) events (p < 0.05). The fraction of early
apoptotic cells did not differ between groups (Fig. 5c–e).
Pericytes from diabetic individuals showed an impaired
migration capacity towards a PDGFB gradient (Fig. 5f).
Pericytes from non-diabetic individuals were able to sup-
port the formation of networks by HUVECs either directly
in a co-culture system or indirectly through factors
contained in their conditioned medium (p < 0.05 vs
HUVECs alone) (Fig. 5g showing representative images
and Fig. 5h showing mean and individual values). These
effects were nullified by diabetes. Moreover, the condi-
tioned medium of diabetic pericytes exerted an inhibitory
effect on HUVEC network formation (p < 0.05 vs
HUVECs alone and p < 0.05 vs conditioned medium of
control pericytes) (Fig. 5g showing representative
images and Fig. 5h showing mean and individual
values). All functional assays were performed under ‘nor-
mal glucose’ conditions, therefore the observed alterations
are compatible with persistent metabolic memory of the
diabetic condition.
Fig. 2 Immunohistochemical
characterisation of CD146+
pericytes in human bone marrow.
(a, b) Representative fluorescence
microscopy images showing that
CD146+ cells (red) express
αSMA (green) (a) and co-localise
with nerve profiles expressing
PGP9.5 (green) (b) in capillaries
of bone marrow from both non-
diabetic and diabetic individuals.
Scale bars, 20 μm. (c)
Immunohistochemistry analysis
of bone marrow vasculature
performed by staining for CD146
(red) and VWF (green). Scale
bars, 50 μm. Arrows point to
PGP9.5- and VWF-positive
structures. (d) Quantification of
VWF-positive capillaries. Data
are expressed as individual values
and mean ± SEM; n=3 per group.
*p<0.05, Student’s t test. (e)
Distribution of arterioles
according to their size. ND, non-
diabetic; T2D, type 2 diabetes
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Diabetes alters the angiocrine activity of bone
marrow pericytes
We next investigated the mRNA levels of angiocrine factors in
pericytes and corresponding protein expression in the condi-
tioned medium. Both ANGPT1 and ANGPT2 mRNA expres-
sion were upregulated in bone marrow pericytes from diabetic
individuals (p < 0.05 both comparisons), whereas TIE2 (also
known as TEK), the gene encoding the ANGPT receptor (ty-
rosine kinase with immunoglobulin and epidermal growth
factor homology domain-2 [TIE2]), remained unchanged
(Fig. 6a–c). VEGFA was not affected by diabetes, whereas
VEGFB was significantly downregulated (p < 0.001 vs the
control group, Fig. 6d,e). This was associated with a decrease
in the gene encoding insulin-like growth factor-binding pro-
tein 2 (IGFBP2) (p < 0.05 for diabetic vs non-diabetic individ-
uals, Fig. 6f), a transcriptional activator of VEGF [35]. In
contrast, the ephrin B2 gene (EFNB2), which reportedly con-
trols VEGFR2 internalisation and signalling [36], was
expressed at a similar level in the two groups (Fig. 6g).
NOTCH signalling in endothelial cells and pericytes acts
downstream of VEGF to shape the vascular network during
angiogenesis [37]. We found that the gene encoding Notch
ligand delta-like 1 (DLK1) was downregulated by diabetes
(p < 0.05 vs non-diabetic individuals), whereas the genes
encoding delta-like 4 (DLK4) and jagged 1 (JAG1) remained
unchanged (Fig. 6h–j). A trio of genes encoding angiogenic
factors—FGF2, CXCL12 and LEP—were downregulated by
Fig. 3 Flow cytometry
assessment of bone marrow
pericytes. Freshly isolated bone
marrow mononuclear cells (BM-
MNCs) were analysed by flow
cytometry for CD146, CD34 and
CD45 markers. (a–e) The gating
strategy consisted of selecting
singlet populations using FSC-
height (FSC-H) by FSC-area
(FSC-A) (a), followed SSC-A by
FSC-A (b) to exclude false-
positive events, which are outside
the indicated boundaries.
Following this, the total BM-
MNC population was gated
according to the expression of the
surface antigen CD34 (c). CD34−
events were gated and further
analysed for CD45 (d). Finally,
the CD45−CD34− cell population
was assessed according to CD146
positivity, using the fluorophore
PE-Cy7-A (e). (f–i) Bar graphs
showing the abundance of
CD146+ (f), CD34−CD146+ (g),
CD45−CD146+ (h) and
CD34−CD45−CD146+ cells (i)
within BM-MNCs from non-
diabetic (n=15) and diabetic
(n=10) individuals. Data are
expressed as individual values
and mean±SEM. Analysis was
performed using Student’s t test.
FSC, forward scatter; ND, non-
diabetic; SSC, side scatter; T2D,
type 2 diabetes
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diabetes (FGF2 an CXCL12, p < 0.01 vs control group; LEP,
p < 0.05 vs control group; Fig. 6k–m). Neuropilins play a
central role in blood vessel physiology as receptors for
semaphorin (SEMA) and VEGF isoforms [38, 39]. Here, we
found diabetes reduced NRP1 transcripts in bone marrow
pericytes and increased SEMA6A (p < 0.05 vs non-diabetic
control individuals for both comparisons, Fig. 6n,o), a known
angiogenesis inhibitor [40]. Diabetes did not alter genes
encoding the two angiogenesis repressors sprouty (SPRY)
[41] and thrombospondin (THBS1) (Fig. 6p,q) [42].
We next performed ELISA of secreted factors in the
pericyte conditioned medium (Fig. 7). Diabetes induced an
increase in immunoreactive ANGPT2 (p < 0.05) but did not
alter ANGPT1, VEGFA, VEGFB, IGFBP2 or SEMA6A (Fig.
7a–e,h). Moreover, FGF2 and CXCL12 were reduced by dia-
betes at the protein level (p < 0.001, Fig. 7f,g).
AKT forced expression and ANGPT2 inhibition rescue
diabetes-induced pericyte dysfunction
AKT activity controls the ability of bone marrow endothelial
cells to secrete angiocrine factors [43, 44] and AKT sup-
presses ANGPT2 secretion [45]. Moreover, type 1 diabetes
inhibits AKT activity in bone marrow endothelial cells [15,
16]. Here, we found that type 2 diabetes does not alter AKT
phosphorylation in bonemarrow pericytes (see electronic sup-
plementary material [ESM] Fig. 1). Nonetheless, AKT might
be uncoupled from downstream signalling. Therefore, we
attempted to rescue the pericytes’ function by either transduc-
ing them with constitutively active myristoylated AKT or
inhibiting ANGPT2 by adding a blocking antibody to the
conditioned medium.
The presence of Ad-myrAKT did not affect the prolifera-
tion, viability or apoptosis of pericytes from non-diabetic in-
dividuals. In contrast, in pericytes from diabetic individuals,
infection with Ad-myrAKT resulted in increased proliferation
(p < 0.01 vs Ad-Null, Fig. 8a), improved pericyte viability
(p < 0.01, Fig. 8b) and reduced late apoptosis (p < 0.05, Fig.
8c–e). In pericytes from the non-diabetic group, Ad-myrAKT
increased the migratory activity of pericytes towards PDGFB
(p < 0.05 vs Ad-Null, Fig. 8f) but did not enhance their angio-
genic activity (Fig. 8g,h). In pericytes from diabetic individ-
uals, Ad-myrAKT blunted the migratory deficit (p < 0.05 vs
Ad-Null) but did not abolished the difference vs non-diabetic
group (p < 0.01, Fig. 8f). Ad-myrAKTabrogated the detrimen-
tal effect of diabetes on the promotion of endothelial network-
ing by pericytes or their conditioned medium (p < 0.01 vs Ad-
Null, Fig. 8g,h). This effect was associated with a reduction in
Fig. 4 Characterisation of CD146+ pericytes following culture expan-
sion. CD146+ pericytes were selected through immunomagnetic sorting
and then expanded. (a, b) Flow cytometry data showing a similar profile
of expanded cells in non-diabetic and diabetic individuals. Cells
expressed CD146, CD105, CD73 and CD90 and were negative for
CD14, CD34, CD45 and CD31. n=6 per group. The bar and whisker
graph shows mean, 25th–75th percentile and minimum and maximum
values (a). Analysis was performed by Student’s t test. (b) Histogram
overlays with positive staining illustrated by the light blue shading and
isotype control by the pink shading. (c) Fluorescent microscopy immu-
nostaining images showing cell positivity for CD146, NG2, nestin,
LEPROT, PDGFRβ, CXCL12 and VEGFR2. Expanded CD146+
pericytes did not express VWF or VE-cadherin. Scale bars, 50 μm. ND,
non-diabetic; T2D, type 2 diabetes
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ANGPT2 (p < 0.05) and an increase in FGF2 levels (p < 0.01)
(Fig. 8i–l).
Addition of an ANGPT2 blocking antibody to the
pericyte conditioned media abrogated the inhibitory ef-
fect of diabetes on promotion of endothelial network
formation (p < 0.01 vs IgG isotype control, Fig. 9a–d),
suggesting that excess production of ANGPT2 may be
accountable for the loss of angiogenic activity of bone
marrow pericytes in diabetes.
Discussion
Pericytes provide support to the vascular endothelium through
direct contacts and paracrine signalling [46]. Furthermore,
stem cell properties [47–50] and reparative capacities
[51–55] have been attributed to pericytes. Under pathological
conditions, such as diabetes [56] and ischaemia [57], dysfunc-
tional pericytes may participate in organ damage. The present
study shows several deficits accrue in bone marrow pericytes
from individuals with type 2 diabetes.
In 2007, Sacchetti et al were the first to demonstrate the
existence of clonogenic CD146+ cells in the bone marrow of
individuals with fibrous dysplasia [27]. These cells express a
host of pericyte markers, such as αSMA, NG2, PDGFRβ and
calponin 1 and 3, secrete JAG1, CXCL12 and ANGPT1 and
are capable of transferring, upon transplantation, the
haematopoietic microenvironment to heterotopic sites.
Subsequently, Corselli et al showed that clonogenically ex-
panded CD34−CD45−CD146+ pericytes from human fetal
bone marrow are capable of establishing multilineage
haematopoiesis in immunodeficient mice. In contrast, unsorted
mesenchymal cells or CD146− cells promoted rapid HSPC
differentiation with consequent loss of engraftment ability
[28]. These studies established the concept that bone marrow
CD146+ cells belong to the class of microvascular pericytes,
represent the human counterpart of murine bone marrow
Cxcl12-abundant reticular cells or nestin+ cells, and play key
Fig. 5 Diabetes alters the functional profile of CD146+ pericytes. Bar
graphs showing the results of BrdU assay (a), MTS assay (b) and flow
cytometry analysis of early (c) and late apoptosis (d). (e) Representative
plots of flow cytometry data shown in (c) and (d). (f) Bar graph showing
the results of the migration assay in which CD146+ pericytes were ex-
posed to a gradient of PDGFB in a transwell chemotactic assay. (g, h)
Representative images (g) and bar graph (h) of the Matrigel assay,
showing a reduced ability of HUVECs to form capillary-like structures
upon co-culture with CD146+ pericytes from individuals with type 2
diabetes or their conditioned medium. n=5 (a–d) or n=3 per group (f,
h). Data are shown as individual values and mean ± SEM; *p<0.05,
**p<0.01 vs non-diabetic group; †p<0.05 vs HUVECs alone, Student’s
t test. AnnV, Annexin V; CM, conditioned medium; ND, non-diabetic;
PC, pericytes; PI, propidium iodide; T2D, type 2 diabetes
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roles in the maintenance and functionality of the vascular
niche, supporting endothelial cell stability and haematopoiesis.
The present investigation compared the abundance,
local isat ion and character is t ics of bone marrow
CD34−CD45−CD146+ pericytes in a cohort of 25 non-
diabetic individuals and 14 individuals with uncomplicated
type 2 diabetes referring to our Orthopaedic Center for hip
reconstructive surgery. We found that bone marrow CD146+
pericytes typically localise around capillaries and sinusoids,
with no evidence of different abundance between samples
from diabetic and non-diabetic individuals, as assessed by in
si tu immunohis tochemistry and f low cytometry.
CD34−CD45−CD146+ pericytes accounted for 0.50% (non-
diabetic) and 0.33% (diabetic) of total BM-MNCs. These fig-
ures are higher than those reported by Sacchetti et al, who
found these cells represent 0.11 ± 0.02% of total BM-MNCs
from bone marrow of individuals with fibrodysplasia, a dis-
ease characterised by ossification of connective tissue [27].
Furthermore, we confirmed that immunosorted
CD34−CD45−CD146+ pericytes could be expanded in culture,
where theymaintain the expression of typical markers, such as
CD105, CD73, CD90, NG2, nestin and PDGFRβ [27, 28].
Importantly, we discovered that pericytes expanded from the
bone marrow of diabetic individuals have functional alter-
ations, such as reduced proliferation, viability and capacity
to migrate towards a chemoattractant stimulus and support
endothelial networking. These alterations were associated
with a distinctive molecular signature. For instance,
CXCL12 was downregulated at mRNA and protein level.
Fig. 7 Diabetes alters the secretome of CD146+ pericytes. Bar graphs
showing results of ELISA for ANGPT1 (a), ANGPT2 (b), VEGFA (c),
VEGFB (d), IGFBP2 (e), FGF2 (f), CXCL12 (g) and SEMA6A (h). Data
are shown as individual values and mean±SEM; n=4–10 (non-diabetic
group) and n=4–9 (diabetic group). *p<0.05, ***p<0.001 vs non-diabetic
group, Student’s t test. ND, non-diabetic; T2D, type 2 diabetes
Fig. 6 Diabetes alters the gene
expression profile of CD146+
pericytes. Bar graphs showing
results of qPCR analysis
performed for ANGPT1 (a),
ANGPT2 (b), TIE2 (c), VEGFA
(d), VEGFB (e), IGFBP2 (f),
EFNB2 (g), DLK1 (h), DLK4
(also known as DLL4) (i), JAG1
(j), FGF2 (k), CXCL12 (l), LEP
(m),NRP (n), SEMA6A (o), SPRY
(p) and THBS1 (q). Data are
expressed as individual values
and mean ± SEM, fold change vs
non-diabetic group; n=6 (non-
diabetic group) or n=4 (diabetic
group). *p<0.05, **p<0.01,
***p<0.001 vs non-diabetic
group, Student’s t test. ND, non-
diabetic; T2D, type 2 diabetes
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Previous studies have highlighted the secretion of CXCL12
by bone marrow stromal cells as representing a pivotal
mechanism essential not only for the steady-state egress and
rapid mobilisation of HSPCs into the circulation but also for
Fig. 8 The presence of Ad-myrAKT rescues the dysfunction of CD146+
pericytes taken from diabetic individuals. CD146+ pericytes from non-
diabetic or diabetic individuals were infected with Ad-myrAKT or Ad-
Null and were then assessed for proliferation (a), viability (b), apoptosis
(c–e) and migration (f). The gating strategy to distinguish different
subfractions of cells based on the expression of Annexin V and PI is
shown in the representative scattergrams (e). CD146+ pericytes from
non-diabetic or diabetic individuals were also assessed for capacity to
support angiogenesis in a Matrigel assay with HUVECs, either in co-
culture (g) or using the CD146+ pericyte conditioned medium (h). (i–l)
Graphs showing the results of ELISA performed on the conditioned
media of CD146+ pericytes from non-diabetic or diabetic individuals
infected with Ad-myrAKT or Ad-Null; ANGPT1 (i), ANGPT2 (j),
FGF2 (k) and CXCL12 (l) were measured. Bar and whisker graphs show
mean, 25th–75th percentile and minimum and maximum values; n=5 per
group. *p<0.05, **p<0.01, ***p<0.001 vs the corresponding Ad-
myrAKT or Ad-Null infected non-diabetic group; †p<0.05 and ††p<0.01
vsAd-Null infected diabetic group, ANOVA followed byBonferroni post
hoc t test. The key in (a) applies to all figure parts. AnnV, Annexin V; ND,
non-diabetic; PerCP, peridinin chlorophyll protein complex; PI,
propidium iodide; T2D, type 2 diabetes
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the maintenance of a proper endothelial cell barrier integrity
[58, 59]. The decrease of CXCL12 in diabetic pericytes is
therefore in keeping with an altered function of the bone mar-
row vascular niche [4, 60].
In addition, the cellular mRNA levels of several angiocrine
factors were altered by diabetes. These included ANGPT1,
ANGPT2 and SEMA6A (upregulated) and VEGFB, IGFBP2,
DLK1, FGF2, LEP and NRP1 (downregulated). We validated
seven of the nine differentially regulated genes by measuring
their protein levels in the pericyte conditioned medium and
found a concordance between transcriptional and post-
transcriptional data for FGF2 and ANGPT2. FGF2 exerts pro-
liferative effects on both pericytes and endothelial cells
through activation of mitogen-activated protein kinases
(MAPK) and AKT, whereas its removal causes withdrawal
from the growth cycle, inducing pericytes to acquire a
smooth-muscle-like contractile phenotype [61]. Moreover,
FGF2 reportedly promotes self-renewal of HSPCs [62].
Stromal cell-produced ANGPT1 plays a pivotal role in the
maintenance of haematopoietic stemness [63]. Moreover,
CD146 or ANGPT1 gene knockout in bone marrow pericytes
reportedly interferes with the pericytes’ ability to direct the re-
modelling of pseudovascular structures, thus suggesting that
ANGPT1 is key for the maintenance of the proper interaction
between pericytes and endothelial cells [33]. In contrast, the roles
of ANGPT2 within the bone marrow vascular niche remain un-
known. Until recently, the vascular ANGPT–TIE2 signalling has
been exclusively related to TIE2 expression by endothelial cells
[64]. ANGPT1 secreted by pericytes binds to TIE2 receptors on
endothelial cells, thus supporting cell survival rate, vessel stability
and endothelial barrier function through the serine kinase AKT–
forkhead box protein O1 signalling pathway [65]. ANGPT2 is
mainly expressed and released by endothelial cells and acts as a
context-dependent weak TIE2 agonist or antagonist and a
destabiliser of endothelial integrity [66]. A recent study showed
that TIE2 receptors are also expressed by pericytes and participate
in the ANGPT-dependent crosstalk with endothelial cells [67].
Our results further integrate the above scheme. In fact, while
confirming human bonemarrow pericytes express ANGPT1 and
TIE2, we also show these cells express and release ANGPT2.
These new data suggest the presence of an autonomous
ANGPT2 signalling in pericytes, integrating the paracrine
ANGPT2 signalling from endothelial cells. Importantly, we
found that bone marrow pericytes from diabetic individuals pro-
duce excess ANGPT2, which may compete with ANGPT1 for
binding to TIE2 on pericytes and endothelial cells. The imbal-
ance between the opposing ANGPTs may contribute to
jeopardising the vascular bone marrow niche at multiple levels.
AKT is co-activated in proliferative vascular cells by
proangiogenic factors, like ANGPT1 and FGF2, but it can also
reciprocally induce a marked upregulation of a spectrum of
angiocrine factors. For instance, activation of AKT in primary
endothelial cells induces the expression of FGF2, IGFBP2 and
ANGPT1, while it suppresses inhibitory factors such as
ANGPT2 and DLK1 [43]. Additionally, selective activation
of AKT in the bone marrow endothelial cells of adult mice
increased long-term haematopoietic repopulation capacity
Fig. 9 Inhibition of ANGPT2 by a blocking antibody restores the ability of
pericytes from diabetic individuals to promote endothelial network forma-
tion. Pericytes from non-diabetic or diabetic individuals were treated with
anti-ANGPT2 antibody or with IgG isotype control. Their conditioned
media was harvested and used to stimulate the formation of networks by
HUVECs on Matrigel. (a, b) Representative images (a) and bar graph (b)
showing that conditioned media of pericytes from diabetic individuals
inhibits endothelial network formation compared with conditioned media
of pericytes from non-diabetic individuals. (c, d) Representative images (c)
and bar graph (d) showing that the inhibition exerted by the conditioned
media of pericytes from diabetic individuals is abrogated by an ANGPT2
blocking antibody. Bar and whisker graphs showmean, 25th–75th percen-
tile and minimum and maximum values. n=3 per group. **p<0.01 vs non-
diabetic, Student’s t test. Ab, antibody; CM, conditioned medium; ND,
non-diabetic; PC, pericyte; T2D, type 2 diabetes
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[43].We found that AKT phosphorylation is not altered in bone
marrow pericytes of diabetic individuals. AKT uncoupling
from associated signalling pathways remains a possible expla-
nation for the observed pericytes’ dysfunctions. In line with
this, transfection with constitutively active Ad-myrAKT abro-
gated pericyte deficits, restored FGF2 and inhibited ANGPT2.
This finding reproduces the functional benefit we observed pre-
viously by reactivating AKT in human bone marrow endothe-
lial cells in a mouse model of type 1 diabetes [15].
Conclusion and future perspectives
This study newly identifies a detrimental effect of type 2 dia-
betes on human bone marrow pericytes, involving the inacti-
vation of the ANGPT–FGF2 angiocrine signalling pathway.
Given the limited group size and the unavailability of recent
HbA1c measurements in some of the participants, it was not
possible to conclude that pericyte dysfunction correlates with
metabolic control. Interestingly, pericytes were expanded and
functionally assessed under in vitro conditions of normal glu-
cose, thus suggesting a persistent memory of the diabetic en-
vironment. These data could have important translational im-
plications and require further investigation. For instance,
pericyte dysfunction might contribute to bone marrow micro-
angiopathy, with an indirect impact on proper mobilisation of
stem/progenitor cells into the circulation. Furthermore, a re-
duced angiocrine signalling from pericytes and endothelial
cells might contribute to alterations of the haematopoietic sys-
tem, including cell-intrinsic alterations of haematopoietic stem
cells, leading to a decline in self-renewal, immune system
dysregulation, predisposition to myeloid neoplasms and de-
layed haematopoietic recovery after myelosuppression.
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